{"url_path":"/sec/fbiop/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061233-index.html","accession_number":"0001104659-26-061233","cik":"0001429260","ticker":"FBIO","issuer_name":"Fortress Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1429260/0001104659-26-061233-index.html","primary_entity_key":"0001429260","primary_entity_name":"Fortress Biotech, Inc."},"word_count":139,"has_tables":true,"body_markdown":"Item 1.      Legal Proceedings\n\nThere are no reportable events or material developments with respect to previously disclosed proceedings for the quarter ended March 31, 2026. To our knowledge, except as previously disclosed, there are no legal proceedings pending against us, other than routine actions and administrative proceedings and other actions not deemed material, that are expected to have a material adverse effect on our financial condition, results of operations, or cash flows. In the ordinary course of business, however, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages.\n\n​\n\n​"}